Formosa Pharmaceuticals and AimMax Therapeutics announce NDA Submission to USFDA for APP13007
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
The eyecirque under eye skin brightening supplement is a unique composition of scientifically proven essential antioxidants, vitamins and minerals
Cumulatively, almost 75% of the health centres in the country have been electrified with a cumulative solar capacity of 3.5 MW
The #pledgemyeyes initiative reached out to over 30 million people across the country and the website registered 3X more pledges compared to the present numbers
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
An algorithm based testing for Fatty Liver Disease
Subscribe To Our Newsletter & Stay Updated